FindTrial
Sign In

expression of b cell leukemia/ lymphoma 2 and Kiel67 in thyroid neoplasms.

Immunohistochemical expression of bcl2 and Ki-67 in thyroid neoplasms. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/05/068134
Enrollment
51
Registered
2024-05-31
Start date
Unknown
Completion date
Unknown
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: O- Medical and Surgical

Interventions

Intervention1: Nil: Nil

Sponsors

Bhagat phool singh government medical college for women khanpur kalan sonipat
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All proven cases of thyroid neoplasms

Exclusion criteria

Exclusion criteria: 1.Non neoplastic lesions of thyroid gland. 2.Blocks which could not be retrieved. 3.Cases who had undergone radiotherapy and chemotherapy

Design outcomes

Primary

MeasureTime frame
To assess the immunohistochemical expression of bcl2 and Ki-67 in thyroidTimepoint: 48 weeks—

Secondary

MeasureTime frame
1.To analyse the various histo-morphological features of thyroid neoplasms. 2.To determine the expression of immunohistochemical marker bcl2 in thyroid neoplasms. 3.To determine the expression of immunohistochemical marker Ki-67 in thyroid neoplasms.Timepoint: 48 weeks—

Countries

India

Contacts

Public ContactVijyendra puri goswami

Bhagat phool singh government medical college for women

swarnkaur123@gmail.com7999740747

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026